Effectiveness of COVID boosters in MS: an update


Two recent studies have reported that COVID boosters can increase the humoral response in MS patients during treatment with ocrelizumab or fingolimod. A number of studies have reported that these disease-modifying therapies (DMT) are associated with a blunted humoral response to COVID vaccination (Achiron et al. Ther Adv Neurol Disord 2021;14:17562864211012835. Gallo et al. Neurol Sci 2021;42:3523-3526). Read More